Affiliation
Department of Endocrinology, Christie Hospital, Manchester, UK. stephen.m.shalet@man.ac.ukIssue Date
2002
Metadata
Show full item recordAbstract
The three most common clinical situations which have given rise to diagnostic and therapeutic issues involve the child treated for: (1) a brain tumour or extracranial tumour with radiotherapy (XRT) which includes an XRT dose of > or =30 Gy to the hypothalamic-pituitary axis; (2) acute lymphoblastic leukaemia with a cranial XRT dose of 18-24 Gy, and (3) haematological malignancy or solid tumour requiring total body irradiation (dose 10-14 Gy) and BMT. The decision about the intent to treat and the timing of GH replacement needs to be taken in collaboration with the paediatric oncologist who will provide guidance about overall prognosis and the risk of relapse. After a dose of > or =30 Gy to the hypothalamic pituitary axis the risk of GH deficiency (GHD) 2 years later is very high (>50%) and therefore there is 'solid' epidemiological evidence, which predicts outcome. Therapeutically the choice is whether or not to offer GH replacement at 2 years in the presence of biochemical evidence of GHD but independent of auxology, or wait until the growth rate declines. Diagnostically the IGF-1 SDS is more useful than previously thought, particularly if XRT-induced GHD is severe; there may, however, be systematic discordancy between the GH responses to different pharmacological stimuli (ITT vs. arginine). For irradiated children in categories 2 and 3, greater emphasis is placed on auxology in determining the need for assessment of GH status. Early rather than very precocious puberty is a real issue and needs to be actively treated with a GnRH analogue if final height appears to be significantly compromised.Citation
Growth and growth hormone status after a bone marrow transplant. 2002, 58 Suppl 1:86-90 Horm. Res.Journal
Hormone ResearchPubMed ID
12373020Type
ArticleLanguage
enISSN
0301-0163Collections
Related articles
- Growth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency.
- Authors: Holm K, Nysom K, Rasmussen MH, Hertz H, Jacobsen N, Skakkebaek NE, Krabbe S, Müller J
- Issue date: 1996 Jul
- Growth and growth hormone status following treatment for childhood leukaemia.
- Authors: Shalet SM, Brennan BM
- Issue date: 1998
- Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy.
- Authors: Gleeson HK, Gattamaneni HR, Smethurst L, Brennan BM, Shalet SM
- Issue date: 2004 Feb
- Growth hormone deficiency after childhood bone marrow transplantation with total body irradiation: interaction with adiposity and age.
- Authors: Davis NL, Stewart CE, Moss AD, Woltersdorf WW, Hunt LP, Elson RA, Cornish JM, Stevens MC, Crowne EC
- Issue date: 2015 Oct
- The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval.
- Authors: Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM
- Issue date: 2003 Jan